Shelter Pharma Ltd (543963) Concall Report Analysis & Insights

Shelter Pharma Ltd

| H2 & FY26 Earnings Conference Call

BULLISH SENTIMENT

⬤27th Jun 26

Summary : Shelter Pharma is a debt-free herbal healthcare company aggressively expanding domestically and internationally, targeting significant revenue growth by 2030, despite recent margin pressures.

Management Perspective positive : Management expresses immense pleasure, confidence in growth targets, and highlights strong financial health (low-debt, internal accruals). They are aggressively expanding and innovating.

Concall Report Analysis & Insights

Business Overview

Shelter Pharma has over 60 years of experience in natural healthcare and wellness.
The company offers nearly 300 herbal formulations for human and animal health.
It combines Ayurveda with modern science, supported by in-house R&D and technology.
Shelter Pharma has a pan-India presence and exports to multiple international markets.
The company is one of three approved by FDCA for drug inspector training in Gujarat.

Future Growth Prospects

Vision FY2030 targets INR 200 Cr annual revenues through capacity expansion and innovation.
A new manufacturing facility near Ahmedabad will significantly enhance production capacity.
New high-value Nutraceutical and herbal products are planned for launch.
Aggressive global market penetration is a core growth pillar, especially in Africa.
The company aims for 40% CAGR for FY27, driven by exports and domestic expansion.

Management Insights

Management is highly thankful to investors and stakeholders for their support.
The company has a strong legacy and trust built over 60 years in the industry.
Shelter Pharma is a low-debt company with high operating efficiency and good return on capital.
They are aggressively expanding sales teams and opening new distribution channels.
The company is confident in achieving its FY2030 revenue target of INR 200 Cr.

Signs of Skepticism

Promoter stake sale was explained as 'internal structuring' without further detail.
EBITDA margins declined in FY26 despite claims of operational efficiencies.
Large loans and advances for raw material purchase were questioned by analysts.
The 200 Cr revenue target by 2030 seems ambitious given current market cap and growth trajectory.
Working capital cycle is high, indicating potential cash flow management challenges.

Risk Factors

EBITDA margins dipped in FY26 due to aggressive expansion and sales team build-up.
Working capital cycle is high at 234 days, though management plans to reduce it.
The company operates in a market with both organized and unorganized players.
Reliance on internal accruals for significant expansion could be a constraint.
Geopolitical events, though currently not impacting, could affect export markets.

Good To Know

India's Ayurvedic products market is projected to grow at 15.52% CAGR from 2026-2034.
Consumer preference is shifting towards natural, chemical-free wellness products.
The Ministry of AYUSH supports standardization, clinical research, and global recognition.
Shelter Pharma's revenue from exports increased by 164% in FY26.
Revenue split is 55% from veterinary and 45% from human healthcare.

Key Drivers

New manufacturing plant capacity.
Aggressive pan-India and export expansion.
Launch of high-margin nutraceuticals.
Debt-free status, internal funding.

Key Analyst Discussions

Competitive Environment

Analysts asked why the company, after 60 years, has a relatively small market cap.
Management stated they are now aggressively expanding beyond their traditional limited mindset.
Lemonade Barley Water product has no significant competition in the market.
The company is expanding its sales team and distribution network across India.
They are exploring government procurement schemes for large volumes.

Financial Highlights

Analysts questioned the purpose and earnings from loans and advances on the balance sheet.
Queries were raised about the dip in EBITDA margins in FY26 despite increased turnover.
Concerns were expressed about the negative cash flow from operations and high working capital cycle.
Management clarified advances are for raw material procurement and export orders.
Management expects EBITDA margins to recover to 22-25% in the next 2-3 years.

Product Composition

Analysts inquired about hero products and their revenue contribution in human and animal health.
Management listed key products like Lemon & Barley Water, Sherolax, Gashoshel, and Nutraceuticals.
They also mentioned veterinary products like mineral mixture and multi-vitamins.
Lemonade Barley Water is a sugar-free diuretic for kidney stone management.
The Lemonade Barley Water product contributes 3.0-3.5 Cr in revenue.

Strategic Considerations

Questions were raised about the impact of war crises on Middle East exports and margins.
Management confirmed no margin reduction due to war, as pharma is essential.
Analysts asked about the 200 Cr revenue guidance by 2030 and if it's conservative.
Management confirmed the guidance is realistic and achievable, not conservative.
Queries about capital raising and operating leverage were answered by relying on internal accruals.